drugmakers
Coverage of drugmakers in the Nexus archive.
- If a Lyme disease vaccine gets approved, how would it go over? We asked hunters
Drugmakers are developing a potential new vaccine to prevent Lyme disease, a tick-borne illness. The article explores how the vaccine might be received amid current vaccine skepticism, particularly among hunters.
- If a Lyme disease vaccine gets approved, how would it go over? We asked hunters
Drugmakers are developing a potential new Lyme disease vaccine to prevent tick-borne illness. The article explores how the vaccine might be received in the context of vaccine skepticism, particularly among hunters.
- STAT+: Trump administration revisits policy to close Medicare drug price negotiation loophole
The Trump administration proposed a policy to prevent drugmakers from evading Medicare price negotiations by adding active ingredients to drugs. The policy aims to finalize the selection of 20 drugs and biologics for negotiation by February 1, 2027, with negotiated prices taking effect in 2029. Medicare typically waits 7 to 11 years after FDA approval before negotiating prices, with biologics requiring longer delays.
- Drugmakers raised prices on hundreds of drugs despite Trump deals, report finds
A report found that drugmakers increased prices on hundreds of drugs despite President Trump's TrumpRx initiative aimed at reducing costs. Trump had announced the program in February 2020, but the analysis revealed ongoing price hikes by pharmaceutical companies.